NetworkNewsBreaks – Champignon Brands Inc. (CSE:
Post# of 25
(Total Views: 204)
Posted On: 08/27/2020 2:56:18 PM
NetworkNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) to Offer Esketamine for Treatment of Adults with MDD at Flagship Clinic
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced that it is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). According to the update, Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic, the Canadian Rapid Treatment Centre of Excellence (“CRTCE”), starting in September 2020. Declared a breakthrough treatment for depression by the US Food and Drug Administration (“FDA”), esketamine was approved by Health Canada for the treatment of MDD in May 2020. “The availability of esketamine at the CRTCE provides tremendous opportunity for adults across Canada affected by treatment-resistant depression to receive an effective, well-tolerated treatment. Moreover, this novel treatment works relatively faster than most conventional treatments for depression,” said Champignon CEO Dr. Roger McIntyre in the press release. “Esketamine has also been observed to help people with MDD when conventional treatments have been insufficient. This provides hope for people affected by MDD to have their symptoms improved and begin to function better again in their lives.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced that it is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). According to the update, Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic, the Canadian Rapid Treatment Centre of Excellence (“CRTCE”), starting in September 2020. Declared a breakthrough treatment for depression by the US Food and Drug Administration (“FDA”), esketamine was approved by Health Canada for the treatment of MDD in May 2020. “The availability of esketamine at the CRTCE provides tremendous opportunity for adults across Canada affected by treatment-resistant depression to receive an effective, well-tolerated treatment. Moreover, this novel treatment works relatively faster than most conventional treatments for depression,” said Champignon CEO Dr. Roger McIntyre in the press release. “Esketamine has also been observed to help people with MDD when conventional treatments have been insufficient. This provides hope for people affected by MDD to have their symptoms improved and begin to function better again in their lives.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Braxia Scientific Corp. (BRAXF) Stock Research Links
Scroll down for more posts ▼